Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

References

• Zhu TY, Tam LS, Lee VW, et al. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(3):568–573.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871–882.
   PubMed Web of Science ®Google Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–318.
   PubMed Web of Science ®Google Scholar
• Iseki K, Miyasato F, Oura T, et al. An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis. 1994;23(4):547–554.
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56:1251–1262.
   PubMed Web of Science ®Google Scholar
• Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol. 2005;32(9):1706–1708.
   PubMed Web of Science ®Google Scholar
• Kuriya B, Gladman DD, Ibanez D, et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):181–185.
   PubMedGoogle Scholar
• McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–643.
   PubMed Web of Science ®Google Scholar
• Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009;5(7):400–404.
   PubMed Web of Science ®Google Scholar
• Gironimi G, Clarke AE, Hamilton VH, et al. Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum. 1996;39:979–987.
   PubMedGoogle Scholar
• Yurkovich M, Vostretsova K, Chen W, et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 2014;66:608–616.
   PubMed Web of Science ®Google Scholar
• Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1–e45.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Mizukami A, Kobayashi A, et al. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study. Int J Rheum Dis. 2018;21(8):1609–1618.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Chiang LK, Rifkin IR. Lupus nephritis. Semin Nephrol. 2006;26(2):95–104.
   PubMed Web of Science ®Google Scholar
• Mok CC. Prognostic factors in lupus nephritis. Lupus. 2005;14(1):39–44.
   PubMed Web of Science ®Google Scholar
• Braun L, Sood V, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–163.
   PubMedGoogle Scholar
• Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009;61:755–763.
   PubMedGoogle Scholar
• Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol. 2012;39(6):531–535.
   PubMed Web of Science ®Google Scholar
• Minowa K, Amano H, Ando S, et al. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: the JUDE study. Mod Rheumatol. 2017;27(1):72–76.
   PubMed Web of Science ®Google Scholar
• JMDC Claims Database: JMDC. 2020. [cited 2020 Jan 17]. Available from: https://www.jmdc.co.jp/en/jmdc-claims-database
   Google Scholar
• Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. Drugs-Real World Outcomes. 2018;5(1):35–43.
   PubMedGoogle Scholar
• Kuwabara H, Saito Y, Mahlich J. Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data. Neuropsychiatr Dis Treat. 2015;11:935–940.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Iwasaki K, Tang W, et al. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5.
   PubMedGoogle Scholar
• Davis KL, Meyers J, Zhao Z, et al. High-risk atherosclerotic cardiovascular disease in a real-world employed Japanese population: prevalence, cardiovascular event rates, and costs. J Atheroscler Thromb. 2015;22(12):1287–1304.
   PubMed Web of Science ®Google Scholar
• Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases. Value in Health. 2003;6(2):90–97.
   PubMed Web of Science ®Google Scholar
• Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol. 2018;8(11):287–301.
   PubMed Web of Science ®Google Scholar
• Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ. 2013;16(5):667–677.
   PubMedGoogle Scholar
• Bertsias G, Ioannidis J, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–2082.
   PubMed Web of Science ®Google Scholar
• Zhang X, Oyama T. Investigating the health care delivery system in Japan and reviewing the local public hospital reform. Risk Manag Healthc Policy. 2016;9:21–32.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Rahman M, Nomura S, et al. Japan health system review. Vol. 8. New Delhi, India: World Health Organization, Regional Office for SouthEast Asia; 2018.
   Google Scholar
• Measures of Underlying Inflation Tokyo, Japan: Bank of Japan. 2020. [cited 2020 Feb 08]. Available from: https://www.boj.or.jp/en/research/research_data/cpi/index.htm/
   Google Scholar
• OECD. Long-term interest rates forecast (indicator). OECD. 2020. [cited 2020 Feb 08]. Available from: https://data.oecd.org/interest/long-term-interest-rates-forecast.htm#indicator-chart
   Google Scholar
• OECD. PPPs and exchange rates: OECD.Stat. 2020. [cited 2020 Feb 08]. Available from: https://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4
   Google Scholar
• Terao C, Yamada R, Mimori T, et al. A nationwide study of SLE in Japanese identified subgroups of patients with clear signs patterns and associations between signs and age or sex. Lupus. 2014;23(13):1435–1442.
   PubMed Web of Science ®Google Scholar
• Tunnicliffe DJ, Singh ‐Grewal D, Kim S, et al. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res. 2015;67:1440–1452.
   PubMed Web of Science ®Google Scholar
• Kan H, Nagar S, Patel J, et al. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016;38(3):610–624.
   PubMed Web of Science ®Google Scholar
• Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(1):i100–i113.
   PubMedGoogle Scholar
• Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014;73(1):154–160.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389–399.
   PubMed Web of Science ®Google Scholar
• Zonana‐Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801–1808.
   PubMed Web of Science ®Google Scholar
• GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus London: GlaxoSmithKline; 2017. [cited 2019 Nov 19]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus/
   Google Scholar